In 2020, the FDA granted orphan drug designation to the PD-L1 antibody durvalumab (Imfinzi) and the CTLA-4 inhibitor tremelimumab (Imjudo) for first-line treatment of HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.